Role of the co-stimulatory molecule inducible T-cell co-stimulator ligand (ICOSL) in the progression of experimental metabolic dysfunction-associated steatohepatitis.
chronic inflammation
galectin-3
liver fibrosis
macrophages
metabolic dysfunction-associated steatotic liver disease
nonalcoholic fatty liver disease
osteopontin
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
09
2023
accepted:
06
11
2023
medline:
11
12
2023
pubmed:
11
12
2023
entrez:
11
12
2023
Statut:
epublish
Résumé
Inducible T-cell Co-Stimulator (ICOS) present on T-lymphocytes and its ligand ICOSL expressed by myeloid cells play multiple roles in regulating T-cell functions. However, recent evidence indicates that reverse signalling involving ICOSL is also important in directing the differentiation of monocyte-derived cells. In this study, we investigated the involvement of ICOS/ICOSL dyad in modulating macrophage functions during the evolution of metabolic dysfunction-associated steatohepatitis (MASH). In animal models of MASH, ICOS was selectively up-regulated on CD8 These results suggest that CD8
Sections du résumé
Background and aims
UNASSIGNED
Inducible T-cell Co-Stimulator (ICOS) present on T-lymphocytes and its ligand ICOSL expressed by myeloid cells play multiple roles in regulating T-cell functions. However, recent evidence indicates that reverse signalling involving ICOSL is also important in directing the differentiation of monocyte-derived cells. In this study, we investigated the involvement of ICOS/ICOSL dyad in modulating macrophage functions during the evolution of metabolic dysfunction-associated steatohepatitis (MASH).
Results
UNASSIGNED
In animal models of MASH, ICOS was selectively up-regulated on CD8
Conclusions
UNASSIGNED
These results suggest that CD8
Identifiants
pubmed: 38077334
doi: 10.3389/fimmu.2023.1290391
pmc: PMC10702974
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1290391Informations de copyright
Copyright © 2023 Provera, Ramavath, Gadipudi, Gigliotti, Boggio, Vecchio, Stoppa, Rolla, Boldorini, Pirisi, Smirne, Albano, Dianzani and Sutti.
Déclaration de conflit d'intérêts
Authors UD, EB, and CG are listed as inventors on the patent PCT/IB2019/050154 “Novel anti-tumor therapeutic agents”. Authors EB, UD, and CG are founders of the University Spin-off NOVAICOS. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Hepatol. 2022 Oct;77(4):1136-1160
pubmed: 35750137
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
JHEP Rep. 2022 Jun 15;4(8):100524
pubmed: 35845296
Front Immunol. 2016 Aug 10;7:304
pubmed: 27559335
Hepatology. 2022 Apr;75(4):1038-1049
pubmed: 35023202
Cancer Cell. 2014 Oct 13;26(4):549-64
pubmed: 25314080
Exp Mol Pathol. 2015 Aug;99(1):155-62
pubmed: 26112094
Lupus. 2009 May;18(6):501-7
pubmed: 19395451
Arthritis Rheum. 2010 Jun;62(6):1723-32
pubmed: 20191584
Front Immunol. 2021 Dec 03;12:786680
pubmed: 34925367
J Physiol. 2023 Apr;601(7):1159-1171
pubmed: 36825510
Immunity. 2020 Sep 15;53(3):641-657.e14
pubmed: 32888418
Mol Cell. 2019 Aug 8;75(3):644-660.e5
pubmed: 31398325
Cell Mol Gastroenterol Hepatol. 2023;15(6):1311-1324
pubmed: 36907380
Hepatology. 2023 Feb 1;77(2):558-572
pubmed: 35712786
Hepatology. 2023 Nov 20;:
pubmed: 37983810
J Immunol. 2013 Feb 1;190(3):1125-34
pubmed: 23275603
J Hepatol. 2018 Feb;68(2):230-237
pubmed: 29128391
Nature. 2021 Apr;592(7854):444-449
pubmed: 33762736
Immunity. 2020 Jun 16;52(6):1057-1074.e7
pubmed: 32362324
J Hepatol. 2022 Nov;77(5):1373-1385
pubmed: 35750138
Cell Rep. 2021 Jan 12;34(2):108626
pubmed: 33440159
J Clin Invest. 2019 Apr 1;129(4):1713-1726
pubmed: 30747722
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):223-238
pubmed: 33349658
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Nature. 2019 Nov;575(7783):512-518
pubmed: 31597160
PLoS One. 2013 Dec 11;8(12):e82163
pubmed: 24349208
Hepatology. 2020 Feb;71(2):477-494
pubmed: 31529720
Hepatology. 2014 Mar;59(3):886-97
pubmed: 24115128
Am J Physiol Gastrointest Liver Physiol. 2020 Feb 1;318(2):G211-G224
pubmed: 31709830
Methods Mol Biol. 2018;1725:301-311
pubmed: 29322426
Nat Rev Immunol. 2022 Jul;22(7):429-443
pubmed: 34741169
J Immunol. 2016 Nov 15;197(10):3905-3916
pubmed: 27798154
Cell Mol Life Sci. 2009 Sep;66(18):3067-80
pubmed: 19603141
Nat Rev Immunol. 2023 Sep;23(9):580-594
pubmed: 36750615
Clin Sci (Lond). 2022 May 13;136(9):643-656
pubmed: 35438166
Immunity. 2020 Sep 15;53(3):627-640.e5
pubmed: 32562600
Nat Rev Gastroenterol Hepatol. 2020 Feb;17(2):81-92
pubmed: 31605031
J Clin Invest. 2021 Feb 15;131(4):
pubmed: 33586673
Lancet. 2021 Jun 5;397(10290):2212-2224
pubmed: 33894145
Commun Biol. 2020 Oct 26;3(1):615
pubmed: 33106594